First-Line Treatment for Amyopathic Dermatomyositis

Initial Treatment Algorithm

The American College of Rheumatology recommends starting with hydroxychloroquine 200 mg twice daily as first-line monotherapy for cutaneous manifestations without muscle weakness, and if this fails at 12 weeks, escalate to methotrexate 15-20 mg/m² weekly combined with oral prednisone 0.5-1 mg/kg/day 1, 2
Patients should begin with hydroxychloroquine 200 mg twice daily (5 mg/kg/day) as monotherapy for cutaneous manifestations without muscle weakness, and combine with rigorous sun protection using SPF 50+ sunscreen and physical barriers to prevent photosensitive rash exacerbations 1, 2
Topical corticosteroids or topical tacrolimus 0.1% can be added for localized symptomatic skin disease (redness or itching) 3, 4, 2
A baseline ophthalmologic examination should be performed before starting hydroxychloroquine, with annual screening within 5 years if retinal toxicity risk factors exist 2
A baseline electrocardiogram should be obtained to screen for QT prolongation before hydroxychloroquine initiation 2

Treatment response should be evaluated at 12 weeks, and if hydroxychloroquine fails, escalate immediately rather than continuing ineffective therapy 1, 2

Methotrexate has stronger guideline-level evidence as the first-line steroid-sparing agent based on multinational guidelines and multiple clinical studies, with significantly earlier prednisone discontinuation and lower cumulative steroid doses compared to other agents 1
The recommended dosing regimen for methotrexate is 15 mg/m² orally once weekly with 1 mg/day folic acid supplementation (or at least 5 mg folic acid per week) 1
Methotrexate has a long-term safety profile acceptable for prolonged use 1

MMF can be used as a second-line agent for patients who fail methotrexate, or as a first-line alternative specifically for severe dermatomyositis skin disease, with a starting dose of 500 mg twice daily, titrated up to 1000-1500 mg twice daily as needed 1, 3, 4
Clinical improvement with MMF typically occurs within 4-8 weeks, though full efficacy may take 3-6 months 1

Intravenous immunoglobulin (IVIG) 1-2 g/kg over 2 consecutive days can be considered for refractory cutaneous disease, leading to improvement or remission in the greatest proportion of patients in systematic reviews 2
Rituximab can be considered as adjunctive therapy for refractory disease, though it may take up to 26 weeks to work 3, 4
Intravenous cyclophosphamide should be considered for severe disease with major organ involvement or extensive ulcerative skin disease 3, 4

For methotrexate, baseline monitoring should include AST, ALT, albumin, CBC, creatinine, chest x-ray, and consider hepatitis B/C serology, with ongoing monitoring of ALT/AST, creatinine, and CBC every 1-1.5 months until stable dose, then every 1-3 months 1
For MMF, regular monitoring of CBC and liver function tests is necessary to detect leukopenia or transaminitis, and patients should be watched for gastrointestinal side effects (nausea, loose stools) 1

Methotrexate should be maintained for at least 12 months after clinical improvement before tapering to ensure prolonged remission 1
MMF should be continued indefinitely as long as disease control is maintained, with consideration of withdrawal only after achieving remission for a minimum of 1 year off corticosteroids 1